NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Price, News & Analysis $6.45 -0.12 (-1.83%) As of 11:33 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Entrada Therapeutics Stock (NASDAQ:TRDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Entrada Therapeutics alerts:Sign Up Key Stats Today's Range$6.35▼$6.6050-Day Range$5.65▼$16.0352-Week Range$4.93▼$16.45Volume25,198 shsAverage Volume301,797 shsMarket Capitalization$250.39 millionP/E RatioN/ADividend YieldN/APrice Target$17.50Consensus RatingHold Company Overview Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs. The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity. Lead programs target lysosomal storage disorders and neuromuscular diseases, with preclinical candidates optimized for tissue tropism and intracellular uptake. Entrada’s technology is designed to be modular, allowing for potential application across multiple therapeutic areas. Founded in Cambridge, Massachusetts, Entrada leverages a team with expertise in protein engineering, cell biology and drug delivery. The company serves patients globally by pursuing regulatory filings in key markets and collaborating with academic partners and contract development organizations. Through continued platform development and strategic partnerships, Entrada seeks to bring novel intracellular therapies from lab to clinic.AI Generated. May Contain Errors. Read More Entrada Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreTRDA MarketRank™: Entrada Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 190th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingEntrada Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialEntrada Therapeutics has a consensus price target of $17.50, representing about 166.4% upside from its current price of $6.57.Amount of Analyst CoverageEntrada Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Entrada Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Entrada Therapeutics are expected to grow in the coming year, from ($4.12) to ($3.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Entrada Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.92% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 4.47.Change versus previous monthShort interest in Entrada Therapeutics has recently increased by 14.54%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.22 News SentimentEntrada Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Entrada Therapeutics this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added Entrada Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have sold 2,156.09% more of their company's stock than they have bought. Specifically, they have bought $29,300.00 in company stock and sold $661,034.00 in company stock.Percentage Held by Insiders9.49% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Entrada Therapeutics' insider trading history. Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRDA Stock News HeadlinesEntrada Therapeutics, Inc. (NASDAQ:TRDA) Given Average Rating of "Hold" by AnalystsJune 15 at 4:22 AM | americanbankingnews.comOppenheimer Remains a Buy on Entrada Therapeutics Inc (TRDA)June 14 at 7:47 AM | theglobeandmail.comA 3M Oz. Historical Gold Resource And A Market That Hasn't Caught UpOne Canadian junior explorer controls a gold and copper system in British Columbia's Kootenay Golden Arc - a district with over 4 million ounces of historical production. Surrounded by major operators including Coeur Mining and Centerra, the project holds a historical resource estimated at 3.31 million ounces of gold. With funding and permits in place for an active drill program and an updated NI 43-101 resource targeted for 2027, the setup offers multiple near-term catalysts - all against a backdrop of gold near record highs and a structurally short copper market.June 16 at 1:00 AM | Wall Street Logic (Ad)Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE)June 9, 2026 | theglobeandmail.comEntrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAJune 4, 2026 | prnewswire.comIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 StudyJune 2, 2026 | markets.businessinsider.comBernhardt Zeiher Buys 5,000 Shares of Entrada Therapeutics (NASDAQ:TRDA) StockMay 22, 2026 | insidertrades.comSee More Headlines TRDA Stock Analysis - Frequently Asked Questions How have TRDA shares performed this year? Entrada Therapeutics' stock was trading at $10.28 on January 1st, 2026. Since then, TRDA stock has decreased by 36.1% and is now trading at $6.57. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) announced its quarterly earnings results on Thursday, May, 7th. The company reported ($0.95) earnings per share for the quarter, beating analysts' consensus estimates of ($1.06) by $0.11. The firm earned $0.88 million during the quarter, compared to analyst estimates of $2.92 million. Entrada Therapeutics had a negative trailing twelve-month return on equity of 51.22% and a negative net margin of 2,895.05%. When did Entrada Therapeutics IPO? Entrada Therapeutics (TRDA) raised $182 million in an initial public offering on Thursday, October 28th 2021. The company issued 9,075,000 shares at a price of $19.00-$21.00 per share. Who are Entrada Therapeutics' major shareholders? Entrada Therapeutics' top institutional investors include Dimensional Fund Advisors LP (0.84%), Renaissance Technologies LLC (0.52%), Bank of New York Mellon Corp (0.20%) and Quantinno Capital Management LP (0.18%). Insiders that own company stock include Bros Advisors Lp Baker, Bioventures 2018 LP Mpm, Kush Parmar, Ventures V LP 5Am, Dipal Doshi, Natarajan Sethuraman, Nathan J Dowden, Kory James Wentworth and Peter S Kim. View institutional ownership trends. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Entrada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entrada Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings5/07/2026Today6/16/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 TRDA's financial health is in the Red zone, according to TradeSmith. TRDA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRDA CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees110Year Founded2016Price Target and Rating Average Price Target for Entrada Therapeutics$17.50 High Price Target$23.00 Low Price Target$10.00 Potential Upside/Downside+171.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$143.75 million Net Margins-2,895.05% Pretax Margin-2,878.28% Return on Equity-51.22% Return on Assets-42.20% Debt Debt-to-Equity RatioN/A Current Ratio13.90 Quick Ratio13.90 Sales & Book Value Annual Sales$25.42 million Price / Sales9.85 Cash FlowN/A Price / Cash FlowN/A Book Value$8.01 per share Price / Book0.81Miscellaneous Outstanding Shares38,820,000Free Float35,137,000Market Cap$250.39 million OptionableOptionable Beta-0.25 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:TRDA) was last updated on 6/16/2026 by MarketBeat.com Staff. From Our PartnersHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredQuick favor to ask youBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
